Journals / Turkish archives of pediatrics (Online) / 2022 / Cilt: 57 - Sayı: 2

Management of Inborn Errors of Immunity in the Genomic Era

Pages
132–145
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The principles of applications learned from these rare monogenic traits, in which the functional impact of the molecular pathways is clear-cut, may be instructive for developing basic concepts toward precision therapy of the common immune-mediated disor- ders, including autoimmunity, infectious diseases, and allergy, which affect mass populations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Inborn errors of immunity are a group of rare diseases characterized by a wide variety of mani- festations, including unusually severe infections, cancer susceptibility, and exaggerated inflam- mation that disrupts organ function.
📊
Key Findings & Data:As of 2022, over 450 gene deficiencies have been classified under ten categories, where numbers are constantly increasing.
💡
Conclusion & Impact:The principles of applications learned from these rare monogenic traits, in which the functional impact of the molecular pathways is clear-cut, may be instructive for developing basic concepts toward precision therapy of the common immune-mediated disor- ders, including autoimmunity, infectious diseases, and allergy, which affect mass populations.
🔬Design:Review & Systematic Survey
📍Scope:2022 Verileri
⚙️Variables:Domain Parameters

Özet

Inborn errors of immunity are a group of rare diseases characterized by a wide variety of mani- festations, including unusually severe infections, cancer susceptibility, and exaggerated inflam- mation that disrupts organ function. As of 2022, over 450 gene deficiencies have been classified under ten categories, where numbers are constantly increasing. The range of inborn errors of immunity varies considerably, from mild infections to serious multisystemic disease. Whereas patients with T cell defects are liable to a broad range of pathogens, selected inborn errors of immunity may predispose hosts merely to a narrow range of microorganisms. Dysregulated immune responses often cause autoimmune manifestations that may target any organ or lead to severe allergies. Therefore, presentation to any medical discipline is possible. Historically, inborn errors of immunity have been associated with short life expectancy and poor life qual- ity, but intensive research into the field has revolutionized this assumption. Especially with the aid of translational investigations, our clinical practice has transformed from a predominantly phenotype-driven management into one that is reinforced by an etiology-driven therapy. This review summarizes the recent advances in molecularly targeted treatment approaches in vari- ous inborn errors of immunity conditions, with many success stories corroborating the power of genomic medicine. The principles of applications learned from these rare monogenic traits, in which the functional impact of the molecular pathways is clear-cut, may be instructive for developing basic concepts toward precision therapy of the common immune-mediated disor- ders, including autoimmunity, infectious diseases, and allergy, which affect mass populations.

🔖

Cite This Article

DEMİR, D. D., ASNAASHARİ, K., REZAEİ, N., ÖZEN, A. (2022). Management of Inborn Errors of Immunity in the Genomic Era. Turkish archives of pediatrics (Online), Cilt: 57 - Sayı: 2, 132–145. https://ajindex.com/articles/418266

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. . Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the international Union of Immunological societies expert committee. J Clin Immu- nol. 2020;40(1):24-64. [CrossRef] 2. Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: an expanding universe. Sci Immunol. 2020;5(49). [CrossRef] 3. Tangye SG, Al-Herz W, Bousfiha A, et al. The ever-increasing array of Novel inborn errors of immunity: an interim update by the IUIS committee. J Clin Immunol. 2021;41(3):666-679. [CrossRef] 4. Bonilla FA, et al. Practice parameter for the diagnosis and man- agement of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e1-e178. [CrossRef] 5. Whittemore R, Knafl K. The integrative review: updated methodol- ogy. J Adv Nurs. 2005;52(5):546-553. [CrossRef] 6. Boyle JM, Buckley RH. Population prevalence of diagnosed pri- mary immunodeficiency diseases in the United States. J Clin Immu- nol. 2007;27(5):497-502. [CrossRef] 7. Podorozhnyĭ PG, Vdovichenko VI, Rozanov EM, et al. Vitamin defi- ciency in patients with ischemic heart disease. Vrach Delo. 1990;9(9):18-19. 8. Ozen A, Baris S, Karakoc-Aydiner E, Ozdemir C, Bahceciler NN, Barlan IB. Outcome of hypogammaglobulinemia in children: immunoglobulin levels as predictors. Clin Immunol. 2010;137(3):374- 383. [CrossRef] 9. Aghamohammadi A, Rezaei N, Yazdani R, et al. Consensus Middle East and North Africa Registry on inborn errors of immunity. J Clin Immunol. 2021;41(6):1339-1351. [CrossRef] 10. Barış HE, Kıykım A, Nain E, Özen AO, Karakoç-Aydıner E, Barış S. The plethora, clinical manifestations and treatment options of autoimmunity in patients with primary immunodeficiency. Turk Pediatr Ars. 2016;51(4):186-192. [CrossRef] 11. de Vries E, European Society for Immunodeficiencies (ESID) members. Patient-centred screening for primary immunodefi- ciency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2012;167(1):108- 119. [CrossRef] 12. Currier R, Puck JM. SCID newborn screening: what we’ve learned. J Allergy Clin Immunol. 2021;147(2):417-426. [CrossRef] 13. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunologi- cal reconstitution of sex-linked lymphopenic immunological defi- ciency. Lancet. 1968;2(7583):1366-1369. [CrossRef] 14. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet. 1968;2